Overview
Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. While clinical effectiveness is an important factor, cost often determines which medication is accessible. This page compares the pricing, insurance landscape, and savings options for both medications as of early 2026.
Neither medication is inexpensive at list price, and out-of-pocket costs vary widely depending on insurance coverage, employer plan design, and eligibility for manufacturer savings programs.
List Prices
The wholesale acquisition cost (list price) for these medications differs, though both represent a significant monthly expense.
Zepbound carries a list price of approximately $1,060 to $1,176 per month, depending on the dose. The price varies across the available maintenance doses (5 mg, 10 mg, and 15 mg), with higher doses generally at the upper end of this range.
Wegovy has a list price of approximately $1,349 to $1,650 per month. This range reflects the different dosing tiers across the titration and maintenance schedule.
It is important to note that list prices rarely reflect what patients actually pay. Negotiated rates between insurers, pharmacy benefit managers, and manufacturers typically result in lower net costs, though those savings do not always reach the patient directly.
Insurance Coverage
Insurance coverage is one of the most significant factors affecting out-of-pocket cost, and it varies considerably between these two medications.
Both Zepbound and Wegovy are approved specifically for weight management rather than diabetes. This distinction matters because many insurance plans, including some Medicare Part D plans and a substantial number of employer-sponsored plans, have historically excluded coverage for weight-loss medications. The anti-obesity medication coverage landscape has been evolving, but gaps remain common.
When coverage is available, plans may impose requirements such as prior authorization, step therapy, or documentation of a specific BMI threshold. Copays under commercial insurance with coverage can range from $25 to several hundred dollars per month, depending on the plan's formulary tier.
Patients are encouraged to verify coverage with their specific plan before starting either medication, as formulary placement and coverage policies can change.
Savings Programs
Both manufacturers offer programs to reduce out-of-pocket costs, though eligibility requirements differ.
Zepbound savings card: Eli Lilly offers a savings card for commercially insured patients that may reduce copays. Eligibility typically excludes patients with government-funded insurance (Medicare, Medicaid, TRICARE).
Lilly Direct self-pay vials: As of December 2025, Eli Lilly began offering Zepbound through its Lilly Direct platform in single-dose vial form at starting prices from $399 per month for self-pay patients. This option is designed for individuals without insurance coverage for the medication and requires use of the vial format rather than the auto-injector pen.
Wegovy savings card: Novo Nordisk offers a savings program for eligible commercially insured patients. The card may reduce out-of-pocket costs to as low as $0 for qualifying patients, though terms and maximum benefit amounts apply. As with the Zepbound card, government-insured patients are generally not eligible.
Telehealth Options
Both medications are available through various telehealth platforms, which may offer bundled pricing that includes the consultation, prescription, and medication. Patients should verify that any telehealth provider is properly licensed and that the medication dispensed is the FDA-approved brand-name product.
Self-Pay Comparison
For patients paying out of pocket, Zepbound is generally less expensive than Wegovy at list price. The Lilly Direct self-pay vials at $399 per month and up have further widened this gap for patients willing to use the vial format. Wegovy does not currently offer a comparable reduced-price self-pay option directly from the manufacturer.
Important Considerations
Cost should be weighed alongside clinical factors. Zepbound and Wegovy contain different active ingredients with different mechanisms of action, and individual response may vary. The decision between them should be made with a healthcare provider who can consider the full clinical picture alongside affordability.
Prices, savings programs, and insurance coverage policies described here are subject to change. Verify current details with your pharmacy, insurer, and the manufacturer's website before making treatment decisions.
Related Pages
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.